LUHUA WANG to Recombinant Fusion Proteins
This is a "connection" page, showing publications LUHUA WANG has written about Recombinant Fusion Proteins.
Connection Strength
0.023
-
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
Score: 0.013
-
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
Score: 0.011